Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.040 +0.010 (+0.49%)
Streaming Delayed Price Updated: 1:05 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Better Gene-Editing Stock: Editas Medicine vs. Bluebird Bio ↗
Neither stock is a good choice for those who can't handle a lot of risk. 
Via The Motley Fool
News headline image
Can This Experimental Gene Therapy Be Enough to Lift Editas Medicine in the Future? ↗
EDIT-301 had positive clinical results in treating sickle cell disease, but the potential payoff is still years in the future. 
Via The Motley Fool
News headline image
2 Reasons to Sell Editas Medicine Stock and 1 Reason to Buy It ↗
Editas Medicine is a high-risk stock with the potential of a big reward. 
Via The Motley Fool
News headline image
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗
For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine. 
Via InvestorPlace
News headline image
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
News headline image
Editas Medicine Earnings Preview ↗
 
Via Benzinga
News headline image
Top CRISPR Stocks ↗
CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses. 
Via Talk Markets
News headline image
Why Editas Medicine Stock Charged Higher in January ↗
The genome-editing company's shares spiked following a definitive agreement with Shoreline Biosciences last month. 
Via The Motley Fool
News headline image
Expert Ratings for Editas Medicine ↗
 
Via Benzinga
News headline image
Thinking of Buying Biotech Stocks? Do These 3 Things First ↗
It's better to plan ahead than to get caught by surprise. 
Via The Motley Fool
News headline image
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
These 2 Biotech Stocks Could Soar in the Next Bull Market ↗
They're both at the cutting edge of gene-editing technology. 
Via The Motley Fool
News headline image
Why Shares of Editas Medicine Jumped This Week ↗
It's been a seesaw month for the clinical-stage gene-editing biotech. 
Via The Motley Fool
News headline image
Shoreline Biosciences Acquires Editas' iNK Cell Franchise, Related Gene Editing Technologies ↗
 
Via Benzinga
Analyst Expectations for Editas Medicine's Future ↗
 
Via Benzinga
News headline image
Why Editas Medicine Stock Is Sliding Today ↗
The gene-editing pioneer announced a big shake-up with its research and development programs. 
Via The Motley Fool
News headline image
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023? ↗
Which of these rebounding biotech stocks is the better buy right now? 
Via The Motley Fool
News headline image
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
3 No-Brainer Stocks to Buy Right Now for Less Than $25 ↗
All three healthcare stocks are showing solid long-term potential. 
Via The Motley Fool
News headline image
Why Editas Medicine's Shares Jumped This Week ↗
The gene-editing biotech's shares have had a strong two-week run. 
Via The Motley Fool
News headline image
Is Editas Medicine Stock a Buy Now? ↗
Layoffs and a thin clinical-stage pipeline aren't very encouraging. 
Via The Motley Fool
News headline image
3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later ↗
CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist. 
Via InvestorPlace
News headline image
Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗
 
Via Benzinga
News headline image
7 CRISPR Stocks With the Best Long-Term Potential ↗
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
News headline image
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate. 
Via MarketBeat
Topics Workforce
News headline image
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
From Editas Medicine, Inc.
Via GlobeNewswire
News headline image
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years ↗
CRISPR could be revolutionary, leading us to put together this list of CRISPR stocks that will make you rich in 10 years. 
Via InvestorPlace
News headline image
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
From Editas Medicine, Inc.
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.